Key Highlights
- 8.36% is the indicated pre-market decline for NewcelX Ltd. (NASDAQ:NCEL) on November 17, 2026, taking the price to USD 2.52 from a calculated prior close of USD 2.7499, a calculated move of -USD 0.2299.
- 14.57 million is the calculated market Capitalization in USD, based on 5.78 million shares outstanding and the indicated price of USD 2.52, which places the stem-cell therapy developer in small-cap territory with high Volatility risk.
- 2.67 million is the USD trailing net loss, equal to USD 0.51 per share, for a clinical-stage company that has no reported Revenue and was founded in 2008 with 12 employees.
- 2 equity financings stand out: USD 1.35 million announced April 1, 2026 at a 30% premium and USD 1.4 million announced July 31, 2026 at a 20% premium, signaling continued dependence on small raises.
What Moved NewcelX Ltd. (NASDAQ:NCEL) in Pre-Market Trading on November 17, 2026 (-USD 0.2299, -8.36%)
The indicated pre-market price for NewcelX Ltd. (NASDAQ:NCEL) is USD 2.52 on November 17, 2026, a pre-market move of -8.36%. The calculated prior close is USD 2.7499 (USD 2.52 divided by 0.9164), and the calculated USD move is -USD 0.2299. Using 5.78 million shares outstanding, the calculated market capitalization is about USD 14.57 million. Published market data showed a price of USD 2.775 on October 21, 2026 and a 52-week range of USD 1.83 to USD 7.64. Pre-market Volume was not found.
The Rationale: No Single Catalyst Identified Beyond FDA Pre-IND Progress for NewcelX Ltd. (NASDAQ:NCEL)
No catalyst for the November 17, 2026 decline was identified in published coverage. As general context, a clinical-stage micro-cap with a small float can move sharply on modest order flow, and pre-market illiquidity widens swings. Company news in 2026 included a Pre-IND package submitted to the FDA for NCEL-101 on May 27, 2026, a successful FDA Pre-IND meeting reported July 1, 2026, a strategic collaboration with Eledon Pharmaceuticals announced March 9, 2026, and the appointment of Dr. Camillo Ricordi to its Scientific Advisory Board on July 8, 2026.
Valuation, Liquidity and Risks for NewcelX Ltd. (NASDAQ:NCEL)
NewcelX develops stem-cell-derived therapies for diabetes, led by NCEL-101 for Type 1 diabetes and Type 2 insulin-dependent diabetes, with other programs including AstroRx for ALS and other neurodegenerative conditions and DOXA for sleep disorders. The trailing net loss was USD 2.67 million, and the company has relied on small equity financings of USD 1.35 million and USD 1.4 million in 2026. Management planned to attend the Breakthrough T1D Congress in Philadelphia on September 28, 2026. Clinical-stage risks include trial timing, regulatory outcomes, financing needs and dilution, and a calculated Market Value under USD 100 million raises volatility.
Where Things Stand
NewcelX Ltd. (NASDAQ:NCEL) is indicated down 8.36% in pre-market trading on November 17, 2026, at USD 2.52, a calculated decline of USD 0.2299 from a prior close of USD 2.7499. No specific catalyst was identified in published coverage. The calculated market capitalization is about USD 14.57 million on 5.78 million shares, the trailing net loss was USD 2.67 million, and the company raised USD 1.4 million in equity on July 31, 2026. Financing needs, clinical timelines and dilution remain central risks, and pre-market moves in thinly traded micro-caps can reverse quickly. This article is informational and is not Investment advice.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...